Conflict of Interest in Cancer Clinical Trials
Kevin B. Knopf, MD MPH, Medical Director, Cancer Commons San Francisco, California Q: Clinical trials are the lifeblood of continuing drug development in the US. Yet they are often undersubscribed. […]
Entries by melindaroberts
Can Preclinical Data Guide Clinical Cancer Therapy?
Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital. Q: Under what circumstances and to what extent are you willing […]
Circadian Cancer Therapy
William Hrushesky, MD FACP, Founder and Chief Scientific Officer Rythmalytics LLC (Cicada Circadian Coach), West Orange NJ; Chief Medical Officer Ambulatory Monitoring Inc., Ardsley, NY Q: Are there meaningful advantages […]
Generic Drugs vs. Biosimilar Biologics
Y. Tony Yang, ScD, LLM, MPH., Associate Professor, Department of Health Administration and Policy, George Mason University, Fairfax, Virginia. Charles Bennett, MD, PhD, M.P.P., Smart State and Frank P and Jose […]
Driver and Passenger Mutations in Cancer Cell Genes
Michelle Turski, PhD, Senior Scientific Knowledge Engineer, CollabRx Q: What are the similarities and differences between “driver” mutations and “passenger” mutations and in what common malignancies is that distinction most […]
Patients and Physicians Should Share Decisions in Oncology
Brian Klepper, PhD, CEO and Founding Principal of Health Value Direct Q: Many of us have been touched by the publication of your sensitive but serious criticism of your wife’s care once her […]
Targeted Therapy for Waldenstrom’s Macroglobulinemia
Javier Munoz MD, FACP, Hematologist/Oncologist at Banner MD Anderson Cancer Center in Gilbert, AZ and Hematology-Oncology Adjunct Assistant Professor at the University of Texas MD Anderson Cancer Center in Houston […]
Using Patient Navigators to Improve Cancer Care
Valerie Fraser Cancer Research Advocate/Patient Navigator; Inflammatory Breast Cancer International Consortium (IBC-IC) Huntington Woods, Michigan Q: What are Patient Navigators and why are they sometimes necessary for some cancer patients. How […]
CollabRx and the 2016 Cancer Moonshot
Q: Did the CollabRx vision of 2008-2010 foretell the 2016 Cancer Moonshot? A: True history is difficult to confirm. Its representation depends in large part on who recorded “his-story.” Even […]
CollabRx and the 2016 Cancer Moonshot
George Lundberg, MS, MD, ScD, MASCP, FCAP, Chief Medical Officer and Editor in Chief, CollabRx, a Rennova Health Company; Editor at Large, Medscape; Executive Adviser, Cureus; Consulting Professor of Pathology […]